secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001193125-24-252194
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Pharma Q3 revenue $128.7M (+25% YoY); GAAP EPS $0.35; raises FY guidance
--------------------------------------------------------------------------------

- Total revenue $128.7M, up 25.3% YoY; GAAP net income $43.9M ($0.35 diluted).
- Non-GAAP net income $71.1M ($0.57 diluted); cash and equivalents $442.3M.
- FIRDAPSE net rev $79.3M (+19.7%); AGAMREE early launch $15.0M; FYCOMPA $32.1M.
- Full-year 2024 total revenue guidance raised to $475-485M.
- Q3 2023 GAAP net loss of $30.8M vs. current net income of $43.9M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312524252194/0001193125-24-252194-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312524252194/d882968d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-252194

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer